Carboplatin, Paclitaxel, Bevacizumab and Vorinostat for Patients With Advanced Non-Small Cell Lung Cancer

• Status: Terminated
• Trial end date: 2016-09-01
• Target enrollment: 0
• Participant gender: All

Summary

The primary objective of the study is to establish the phase II recommended dose of Vorinostat when administered in combination with the regimen of carboplatin, paclitaxel and bevacizumab for patients with previously untreated advanced non-small cell lunc cancer.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Milton S. Hershey Medical Center
• Treatments: Albumin-Bound Paclitaxel; Bevacizumab; Carboplatin; Paclitaxel; Vorinostat

Criteria

Inclusion Criteria:

• Advanced non-squamous NSCLC

• No prior chemotherapy for advanced disease

• ECOG performance status 0 or 1

• Measurable disease

• Life expectancy > 3 months

• Normal bone marrow, renal and hepatic function

• Ability to take oral medications

• Willingness to sign informed consent

Exclusion Criteria:

• History of brain metastasis

• Evidence of thromboembolic phenomenon and treatment with anticoagulants

• Pregnancy

• Uncontrolled inter-current illness

• Prior therapy with Paclitaxel